Ventripoint Announces Debt Settlement Agreements

Executive Summary

• Ventripoint Diagnostics Ltd. will settle $542,591.50 of debt to arm’s‑length creditors by issuing 5,425,915 common shares at $0.10 per share.
• The share issuance is subject to a four‑month and one‑day hold period and requires TSX Venture Exchange approval.
• The transaction preserves cash for the company’s ongoing business development activities.

Key Details

• Debt Amount: $542,591.50 total indebtedness to arm’s‑length creditors.
• Share Issuance: 5,425,915 common shares at a price of $0.10 per share (aggregate gross consideration of $542,592).
• Hold Period: Shares will be subject to a lock‑up of four months and one day from the date of issuance.
• Purpose: Settlement of debt to conserve cash for product development and other corporate initiatives.
• Regulatory Condition: Issuance is contingent upon approval by the TSX Venture Exchange.
• Contact: Hugh MacNaught – [email protected] – 604‑671‑4201

Notable Quotes

(No executive quotes were included in the release.)